



THE JOURNAL OF  
**CLINICAL PSYCHIATRY**

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

## **Supplementary Material**

**Article Title:** Preventive Effects of Suvorexant on Delirium: A Randomized Placebo-Controlled Trial

**Author(s):** Kotaro Hatta, MD, PhD; Yasuhiro Kishi, MD, PhD; Ken Wada, MD, PhD; Takashi Takeuchi, MD, PhD; Shigeo Ito, MD, PhD; Akiko Kurata, MD, PhD; Kazunori Murakami, MA; Manabu Sugita, MD, PhD; Chie Usui, MD, PhD; and Hiroyuki Nakamura, MD, PhD; for the DELIRIA-J Group


**DOI Number:** 10.4088/JCP.16m11194

### **List of Supplementary Material for the article**

1. [eFigure 1](#) Changes in Delirium Rating Scale-Revised-98-J Total Score in the Suvorexant Group and Placebo Group
2. [eFigure 2](#) Changes in Delirium Rating Scale-Revised-98-J Severity Scale Score in the Suvorexant Group and Placebo Group
3. [eFigure 3](#) Changes in Sleep-Wake Cycle Disturbance Score (Item #1) of DRS-R98-J in the Suvorexant Group and Placebo Group


### **Disclaimer**

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.




**eFigure 1: Changes in Delirium Rating Scale-Revised-98-J Total score in the suvorexant group and placebo group.**

To test for the effects of treatment on Delirium Rating Scale-Revised-98-J (DRS-R98-J) Total score, two- (suvorexant and placebo) by-four (day 1, day 2, day 3, and day 4 time points) repeated-measures ANOVA was used. \*Repeated-measures ANOVA revealed a significant main effect of treatment ( $F=4.59$ ,  $P=.036$ ) and interaction ( $F=2.94$ ,  $P=.045$ ), but no significant main effect of time course ( $F=1.21$ ,  $P=.30$ ) on DRS-R98-J Total score.



**eFigure 2: Changes in Delirium Rating Scale-Revised-98-J Severity scale score in the suvorexant group and placebo group.** To test for the effects of treatment on Delirium Rating Scale-Revised-98-J (DRS-R98-J) Severity scale score, two- (suvorexant and placebo) by-four (day 1, day 2, day 3, and day 4 time points) repeated-measures ANOVA was used. \*Repeated-measures ANOVA revealed a significant main effect of treatment ( $F=5.03$ ,  $P=.028$ ) and interaction ( $F=3.53$ ,  $P=.026$ ), but no significant main effect of time course ( $F=1.17$ ,  $P=.32$ ) on DRS-R98-J Severity scale score.



**eFigure 3: Changes in Sleep-wake cycle disturbance score (item #1) of DRS-R98-J in the suvorexant group and placebo group.** To compare Sleep-wake cycle disturbance score (item #1) of DRS-R98-J between the suvorexant group and placebo group over the study period, ANOVA was used. \*ANOVA did not reveal significant main effect of time course ( $F=0.08$ ,  $P=.97$ ) and interaction ( $F=0.19$ ,  $P=.90$ ), but revealed a tendency for main effect of treatment ( $F=3.79$ ,  $P=.053$ ) on Sleep-wake cycle disturbance score (item #1) of DRS-R98-J.